At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 102 enrolled
Drug / intervention
Opelconazole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Controlled Open-label Study to Assess the Safety and Tolerability of Nebulized PC945 for Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)
In Brief
A Phase 2 clinical trial evaluating Opelconazole and Standard of Care for Pulmonary Aspergillosis. Completed, enrolled 102 participants across 19 sites in 2 countries.
Detailed Summary
A study to evaluate the safety and tolerability of opelconazole for the prevention of fungal aspergillus infections in the lung in participants who have received a lung transplant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Aspergillosis
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedSep 2021
Enrollment StartNov 2021
Primary CompletionOct 2023
Study CompletionNov 2023
TodayJul 2026
First PostedSep 8, 2021
Enrollment StartNov 19, 2021
Primary CompletionOct 19, 2023
Study CompletionNov 13, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 4.8 years ago
Interventions
Opelconazoledrug
Nebulizer suspension
Standard of Caredrug
Standard of Care